STOCK TITAN
  1. Home
  2. News
  3. ABCL

AbCellera Biologics Inc - ABCL STOCK NEWS

Welcome to our dedicated news page for AbCellera Biologics (Ticker: ABCL), a resource for investors and traders seeking the latest updates and insights on AbCellera Biologics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AbCellera Biologics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AbCellera Biologics's position in the market.

News
AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023
Rhea-AI Summary
AbCellera (ABCL) to Present at Piper Sandler 35th Annual Healthcare Conference on November 30, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.05%
Tags
conferences
-
News
AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023
Rhea-AI Summary
AbCellera presented new data at the SITC Annual Meeting on its T-cell engager (TCE) programs. The data show that TCE function is determined by multiple factors, including CD3-binding affinity. AbCellera has developed a high-throughput process to select diverse CD3-binding antibodies for different tumor targets. They also presented data on their MAGE-A4 x CD3 program, demonstrating the platform's ability to generate high-quality TCEs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.09%
Tags
none
-
News
AbCellera Reports Q3 2023 Business Results
Rhea-AI Summary
AbCellera (Nasdaq: ABCL) reported total revenue of $6.6 million in Q3 2023, compared to $101.4 million in Q3 2022. The net loss was $28.6 million, compared to net earnings of $26.6 million in Q3 2022. The company reached a cumulative total of 182 programs under contract with 42 different partners and had 110 partnered program starts. AbCellera advanced two AbCellera-led programs into IND-enabling studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.09%
Tags
earnings
News
AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023
Rhea-AI Summary
AbCellera (Nasdaq: ABCL) executives will present at the Jefferies London Healthcare Conference on November 14, 2023. A live webcast will be available on AbCellera's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.24%
Tags
conferences
-
News
AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023
Rhea-AI Summary
AbCellera to announce Q3 2023 financial results and hold earnings conference call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.34%
Tags
conferences earnings
-
News
AbCellera Announces Two T-Cell Engager Presentations at SITC 2023
Rhea-AI Summary
AbCellera announces two upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. The presentations will focus on their T-cell engager platform and its application in various tumor targets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
none
News
AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron
Rhea-AI Summary
AbCellera expands collaboration with Regeneron, increasing the number of targets from 4 to 8.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology
Rhea-AI Summary
AbCellera and Incyte enter strategic collaboration to develop therapeutic antibodies in oncology
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
none
-
News
AbCellera Reports Q2 2023 Business Results
Rhea-AI Summary
AbCellera announces financial results for Q2 2023, reporting total revenue of $10 million, a net loss of $30.5 million, and a cumulative total of 106 partnered program starts. The company secured over $220 million in strategic financing, bringing their total available liquidity to over $1 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.34%
Tags
earnings
News
AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights’ Request for Rehearing
Rhea-AI Summary
AbCellera (Nasdaq: ABCL) - PTAB Rejects Berkeley Lights' Request for Rehearing on AbCellera's Patent Validity - The United States Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has denied Berkeley Lights' rehearing request in an Inter Partes Review (IPR) filed to challenge AbCellera’s U.S. Patent No. 10,087,408. The '408 Patent covers microfluidic devices and their use in culturing cells, monitoring responses, and recovering selected cells, crucial for AbCellera’s monoclonal antibody development. PTAB confirmed the validity of all '408 Patent claims, reinforcing AbCellera's intellectual property strength.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
none
Stock ABCL logo
AbCellera Biologics Inc

Nasdaq:ABCL

ABCL Rankings

#2353 Ranked by Market Cap
#5068 Ranked by Stock Gains
N/A Ranked by Dividends

ABCL Stock Data

1.19B
191.76M
28.09%
43.66%
8.06%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
CA
Vancouver

About ABCL

abcellera is a canadian biotechnology company focused on accelerating the discovery of monoclonal antibody (mabs) therapeutics. antibodies are molecules that are naturally produced by the immune system of humans or animals to fight off infection and disease. the unique property of antibodies is that they can specifically recognize and target diseased cells or pathogens, making them precise and highly effective drugs with low side effects for the treatment of cancer, autoimmune disorders and infections. the immune system is capable of making billions to trillions of unique antibodies, each produced by a single immune cell. of these, only a select few are suitable for therapeutic applications. finding these rare antibodies presents a major roadblock in the development of new therapeutics. abcellera addresses this bottleneck by using microfluidic technology for the rapid and high-throughput analysis of antibodies directly from single cells. abcellera is a spinoff from dr. carl hansen’